Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $68.92

Tempus AI, Inc. (NASDAQ:TEM) has received an average rating of “Hold” from the sixteen research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $68.9231.

TEM has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Freedom Capital raised Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Jefferies Financial Group initiated coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Tempus AI in a research report on Friday, July 24th.

Insider Transactions at Tempus AI

In other news, CEO Ryan Fukushima sold 33,284 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer owned 167,763 shares in the company, valued at approximately $9,627,918.57. This represents a 16.56% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jennifer A. Doudna sold 2,673 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $147,015.00. Following the transaction, the director directly owned 25,942 shares of the company’s stock, valued at $1,426,810. The trade was a 9.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 699,793 shares of company stock worth $33,763,231. 24.26% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Aberdeen Group plc increased its position in shares of Tempus AI by 64.2% during the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after purchasing an additional 102,878 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in Tempus AI by 291.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after buying an additional 36,096 shares in the last quarter. Bogart Wealth LLC boosted its position in Tempus AI by 365,087.5% in the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after buying an additional 58,414 shares in the last quarter. Eagle Health Investments LP bought a new stake in Tempus AI during the first quarter worth about $11,588,000. Finally, Alethea Capital Management LLC bought a new stake in Tempus AI during the fourth quarter worth about $1,863,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q2 results beat expectations. Tempus reported an adjusted loss of $0.04 per share, narrower than the $0.14 consensus loss and improved from a $0.22 loss a year earlier. Revenue increased 21.6% year over year to $382.5 million, modestly above estimates. Tempus AI Q2 earnings report
• Positive Sentiment: Management raised or reaffirmed strong 2026 growth expectations. Full-year revenue guidance is approximately $1.595 billion to $1.605 billion, supported by momentum in oncology diagnostics, data and modeling. Tempus also outlined a potential $400 million revenue uplift by 2028 tied to its xT CDx and xF products. Tempus revenue outlook
• Positive Sentiment: Analyst support remains favorable. Needham reaffirmed its Buy rating and set a $75 price target, implying substantial upside from recent trading levels. Needham analyst rating
• Negative Sentiment: The earnings beat did not fully resolve profitability concerns. Tempus remains unprofitable, with a negative net margin and analysts projecting a full-year loss. Revenue guidance is broadly consistent with expectations rather than a major upside surprise, contributing to the post-earnings reset. Tempus earnings call highlights
• Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares. The $10.5 million sale reduced his direct holdings by more than half. Although it was conducted under a pre-arranged Rule 10b5-1 plan, the transaction can still weigh on sentiment, particularly while the stock trades well below its 52-week high. Tempus CEO stock sale

Tempus AI Stock Down 0.9%

Shares of TEM opened at $43.87 on Wednesday. The company has a 50-day simple moving average of $51.40 and a 200-day simple moving average of $52.70. The firm has a market capitalization of $7.88 billion, a P/E ratio of -30.47 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. Tempus AI has a 52 week low of $40.77 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 49.56% and a negative net margin of 17.77%.The business had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the business earned ($0.22) earnings per share. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, equities research analysts expect that Tempus AI will post -1.35 earnings per share for the current year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.